Sherry R. Pierce

1.8k total citations
14 papers, 1.1k citations indexed

About

Sherry R. Pierce is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Sherry R. Pierce has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 9 papers in Genetics and 5 papers in Oncology. Recurrent topics in Sherry R. Pierce's work include Acute Myeloid Leukemia Research (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Sherry R. Pierce is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Sherry R. Pierce collaborates with scholars based in United States, Netherlands and United Kingdom. Sherry R. Pierce's co-authors include Hagop M. Kantarjian, Elihu H. Estey, Farhad Ravandi, Jörge E. Cortes, Gautam Borthakur, Guillermo Garcia‐Manero, Michael Andreeff, Marina Konopleva, Frederick R. Appelbaum and Mark Brandt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Sherry R. Pierce

13 papers receiving 1.0k citations

Peers

Countries citing papers authored by Sherry R. Pierce

Since Specialization

Citations

This map shows the geographic impact of Sherry R. Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherry R. Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherry R. Pierce more than expected).

Fields of papers citing papers by Sherry R. Pierce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherry R. Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherry R. Pierce. The network helps show where Sherry R. Pierce may publish in the future.

Co-authorship network of co-authors of Sherry R. Pierce

This figure shows the co-authorship network connecting the top 25 collaborators of Sherry R. Pierce. A scholar is included among the top collaborators of Sherry R. Pierce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherry R. Pierce. Sherry R. Pierce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis 2017 ·Blood Advances ·Prajwal Boddu, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Farhad Ravandi, Srđan Verstovšek, Elias Jabbour, Gautam Borthakur, Marina Konopleva, Kapil N. Bhalla, Naval Daver, Courtney D. DiNardo, Christopher B. Benton, Koichi Takahashi, Zeev Estrov, Sherry R. Pierce, Michael Andreeff, Jörge E. Cortes, Tapan M. Kadia	71
2	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase 2015 ·Leukemia Research ·Talha Badar, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Jörge E. Cortes, Naveen Pemmaraju, Sherry R. Pierce, Kate J. Newberry, Naval Daver, Srđan Verstovšek	57
3	Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center 2014 ·Leukemia ·Roland B. Walter, Megan Othus, Alan K. Burnett, (unknown), H. Kantarjian, Gert J. Ossenkoppele, Robert K. Hills, Farhad Ravandi, Thomas Pabst, Anna Evans, Sherry R. Pierce, Marie‐Christiane Vekemans, (unknown), Elihu H. Estey	116
4	Safety and clinical activity of 5‐aza‐2′‐deoxycytidine (decitabine) with or without Hyper‐CVAD in relapsed/refractory acute lymphocytic leukaemia 2014 ·British Journal of Haematology ·Christopher B. Benton, Deborah A. Thomas, Hui Yang, Farhad Ravandi, Michael Rytting, Susan O’Brien, Anna R. Franklin, Gautam Borthakur, Samuel Dara, Monica Kwari, Sherry R. Pierce, Elias Jabbour, Hagop M. Kantarjian, Guillermo Garcia‐Manero	33
5	Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia 2014 ·Blood ·(unknown), Jeffrey L. Jorgensen, Hagop M. Kantarjian, Elias Jabbour, Sherry R. Pierce, Mark Brandt, Sa A. Wang, Sergej Konoplev, Marina Konopleva, Steven M. Kornblau, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Michael Andreeff, Zeev Estrov, Guillermo Garcia‐Manero, Jörge E. Cortes, Farhad Ravandi	2
6	Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients 2013 ·Blood ·Roland B. Walter, Megan Othus, Alan K. Burnett, Bob Löwenberg, Hagop M. Kantarjian, Gert J. Ossenkoppele, Robert K. Hills, (unknown), Farhad Ravandi, Anna Evans, Sherry R. Pierce, Frederick R. Appelbaum, Elihu H. Estey	78
7	Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy 2013 ·Blood ·(unknown), Hagop M. Kantarjian, Farhad Ravandi, Susan O’Brien, Guillermo Garcia‐Manero, Michael Andreeff, Marina Konopleva, Elias Jabbour, Sherry R. Pierce, Gautam Borthakur, Jörge E. Cortes	2
8	Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report 2013 ·Blood ·Farhad Ravandi, Megan Othus, Stefan Faderl, Derek L. Stirewalt, Sherry R. Pierce, Gautam Borthakur, John E. Godwin, Jeanne E. Anderson, Stephen H. Petersdorf, Jörge E. Cortes, Fabiana Ostronoff, (unknown), Frederick R. Appelbaum, Hagop M. Kantarjian, Elihu H. Estey	1
9	Incidence Of and Risk Factors For Acute Myeloid Leukemia Involvement Of The Central Nervous System 2013 ·Blood ·Uri Rozovski, Maro Ohanian, Farhad Ravandi, Guillermo Garcia‐Manero, Stefan Faderl, Jörge E. Cortes, Sherry R. Pierce, (unknown), Zeev Estrov	0
10	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center 2013 ·Blood ·Roland B. Walter, Megan Othus, Alan K. Burnett, Bob Löwenberg, Hagop M. Kantarjian, Gert J. Ossenkoppele, Robert K. Hills, Farhad Ravandi, Anna Evans, Sherry R. Pierce, Frederick R. Appelbaum, Elihu H. Estey	3
11	Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome 2012 ·Journal of Clinical Oncology ·Guillermo Garcia‐Manero, Francesco Paolo Tambaro, N. Bekele, Hui Yang, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Tapan M. Kadia, Marina Konopleva, Stefan Faderl, Jörge E. Cortes, Mark Brandt, Yumin Hu, Deborah McCue, Willie Newsome, Sherry R. Pierce, Marcos de Lima, Hagop M. Kantarjian	124
12	Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia 2010 ·Journal of Clinical Oncology ·Farhad Ravandi, Jörge E. Cortes, Daniel M. Jones, Stefan Faderl, Guillermo Garcia‐Manero, Marina Konopleva, Susan O’Brien, Zeev Estrov, Gautam Borthakur, Deborah A. Thomas, Sherry R. Pierce, Mark Brandt, Anna Byrd, B. Nebiyou Bekele, Keith W. Pratz, Rajyalakshmi Luthra, Mark J. Levis, Michael Andreeff, Hagop M. Kantarjian	282
13	The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations 2006 ·British Journal of Haematology ·Frederick R. Appelbaum, Kenneth J. Kopecky, Martin S. Tallman, Marilyn L. Slovak, Holly Gundacker, Haesook T. Kim, Gordon W. Dewald, Hagop M. Kantarjian, Sherry R. Pierce, Elihu H. Estey	187
14	Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia 1999 ·Journal of Clinical Oncology ·Miloslav Beran, Elihu H. Estey, Susan O’Brien, Jörge E. Cortes, Charles Koller, Francis J. Giles, Steven M. Kornblau, Michael Andreeff, Norbert Vey, Sherry R. Pierce, Kimberly Hayes, Gee Chuan Wong, Michael J. Keating, Hagop M. Kantarjian	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact